Recent Patents on the Development of c-Met Kinase Inhibitors

Author(s): Xiangming Xu, Lei Yao*

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 15 , Issue 3 , 2020

Become EABM
Become Reviewer
Call for Editor


Background: Receptor Tyrosine Kinases (RTKs) play critical roles in a variety of cellular processes including growth, differentiation and angiogenesis, and in the development and progression of many types of cancer. Mesenchymal-Epithelial Transition Factor (c-Met) kinase is one of the types of RTKs and has become an attractive target for anti-tumor drug designing. c-Met inhibitors have a broad prospect in tumor prevention, chemotherapy, biotherapy, and especially in tumor resistance.

Objective: The purpose of this article is to review recent research progress of c-Met inhibitors reported in patents since 2015.

Methods: A comprehensive Scifinder and Web of Science literature review was conducted to identify all c-Met inhibitors published in patents since 2015.

Results: There are two kinds of c-Met inhibitors, one is from natural products, and the other one is of synthetic origin. Most of these c-Met inhibitors show potent in vivo and in vitro antitumor activities and have potential in the treatment of cancers.

Conclusion: c-Met kinase inhibitors have emerged as an exciting new drug class for the treatment of all kinds of cancers, especially the Non-Small Cell Lung Cancer (NSCLC) with tumor resistance. More studies should be conducted on natural products to find novel c-Met kinase inhibitors.

Keywords: Cancer, c-Met, inhibitors, patent, progress, receptor tyrosine kinases.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Published on: 07 December, 2020
Page: [228 - 238]
Pages: 11
DOI: 10.2174/1574892815666200630102344
Price: $65

Article Metrics

PDF: 37